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ABSTRACT
Adverse reactions to foods and adverse drug reactions are inherent in product defects, medication
errors, and differences in individual drug exposure. Pharmacogenetics is the study of genetic
causes of individual variations in drug response and pharmacogenomics more broadly involves
genome-wide analysis of the genetic determinants of drug efficacy and toxicity. The similarity of
nutritional genomics and pharmacogenomics stems from the innate goal to identify genetic var-
iants associated with metabolism and disease. Thus, nutrigenomics can be thought of as encom-
passing gene–diet interactions involving diverse compounds that are present in even the simplest
foods. The advances in the knowledge base of the complex interactions among genotype, diet,
lifestyle, and environment is the cornerstone that continues to elicit changes in current medical
practice to ultimately yield personalized nutrition recommendations for health and risk assess-
ment. This information could be used to understand how foods and dietary supplements uniquely
affect the health of individuals and, hence, wellness. The individual’s gut microbiota is not only
paramount but pivotal in embracing the multiple-functional relationships with complex metabolic
mechanisms involved in maintaining cellular homeostasis. The genetic revolution has ushered in
an exciting era, one in which many new opportunities are expected for nutrition professionals
with expertise in nutritional genomics. The American College of Nutrition’s conference focused on
“Personalized Nutrition: Translating the Science of NutriGenomics Into Practice” was designed
to help to provide the education needed for the professional engagement of providers in the
personalized medicine era.
KEYWORDS
Personalized nutrition;
nutritional genomics;
pharmacogenomics; single
nucleotide polymorphism;
next generation
sequencing; gene–diet
interactions; metabolic
diseases; wellness and
genomics; Alzheimer’s
disease and cognitive
decline; autoimmune
diseases; overt
inflammation and chronic
diseases; gut microbiome
Introduction
Nutritional genomics is the study of the effects of foods and food
constituents on gene expression. Nutritional genomics aims to
develop a rational means to optimize nutrition through the iden-
tification of the person’s genotype and this defines the relation-
ship between nutrients and human health. Individuals cannot
change their genetics, but they can eat the right foods to support
genetic predispositions, take the right supplements to support
gene variations, and promote normal cell function and structure.
Indeed, poor diet can be a risk factor of disease. Given that diet-
ary components can alter gene expression and that the degree to
which diet influences health and disease depend upon an indi-
viduals genetic make up, the use of pharmacogenomics technolo-
gies should be well defined in order to fully embrace their
potential application for diagnostic and prognostic purposes.
There are many inroads ahead in this realization.
Single nucleotide polymorphisms are now recognized as the
main cause of human genetic variability and are already a
valuable resource for mapping complex genetic traits. The
identification and validation of accurate biomarkers of
individual responses to drug or biologic treatment remain pre-
requisite conditions ascribed to the development of personal-
ized medicine and other evolving therapeutic strategies. The
sequence variations in the genes for proteins involved in drug
disposition can alter the pharmacokinetics of a drug, while
sequence variations in drug target genes can change the
pharmacodynamics of the drug (Figure 1). That pharmacogen-
omics connects genotype to patient-specific treatment intrin-
sically implies that individuals have variations in the
composition of their genetic characteristics (factored on strat-
egies that embrace testing for candidate-genes and genome-
wide association) that will affect the availability of functional
proteins, which ultimately impacts functional homeostasis and
the outcome of drug therapy. Primary candidate genes include
those encoding for drug receptors, metabolizing enzymes, and
transporters. However, selection of optimal drug therapy may
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also involve disease susceptibility genes indirectly affecting
drug response (Figure 1) (1). This meeting report presents a
range of the subject matter covered at the conference depicting
the key essence of nutrigenomics and its translation to person-
alized nutrition benefits and health. The context of the report
is limited to the areas of expertise of the presenters/authors
and each section included is reflective of the individual pre-
senter/author’s presentation at the conference and is not a
reflection of a position by the American College of Nutrition
(ACN). For additional information on ACN programs and
meetings, visit www.americancollegeofnutrition.org.
Understanding genomics
The conference was prefaced with a session entitled
“NutriGenomics Primer: Foundational Concepts for Clinical
Practice,” which emphasized the understanding genomics
with a focus on nutrigenomics and clinical assessment and
genomic validation (Figure 1). The molecular basis of dis-
ease provides the means for personalizing therapy with the
expectation of increased therapeutic efficacy as the outcome.
Because genetics is integrated into health care, medical,
pharmacologic, and nutritional therapies will become more
oriented toward the genotype of each person. Nutrition
assessment and intervention will be the keys to preventing
or mitigating the expression of diseases to which an individ-
ual is susceptible; essentially visualizing the potential interac-
tions of the components of foods (Figure 2) can interact
with the genetic material to produce biomolecules that work
to maintain cellular homeostasis.
Understanding the difference between genomics and genet-
ics, how various single nucleotide polymorphisms (SNPs)
work to convey risk or benefit to an individual not just alone
but also in combination and how methylation and other fac-
tors contribute to the expression of DNA are imperative con-
cepts for the practitioner wanting to use genomics as part of
their arsenal of tools. With regard to SNPs, it is important for
clinicians to understand that every individual has about 3 mil-
lion SNPs among their 3 billion base pairs found in the DNA
and that these SNPs are what makes each of us unique. SNPs
are not innately bad or good, but some SNPs, particularly
some of those found in promotor regions or other key regions
such as those effecting methylation sites, can have a profound
effect on gene transcription. Each of these genes can then con-
tribute to having more or less of key enzymes, receptors, vita-
mins, inflammatory mediators, neurotransmitters, and more.
Most of the health issues facing modern society (obesity, heart
disease, osteoporosis, diabetes, Alzheimer’s disease, and macu-
lar degeneration) are due to complicated polygenic causes.
Expanded knowledge of genomics can facilitate a better
understanding of the pathophysiology of an individual’s vari-
ous health risks and better modulate these risks with custom-
ized personalized prevention and intervention strategies. For
example, individuals with multiple SNPs in the signal trans-
ducer and activators of transcription 3 (STAT3) pathway will
tend to store fat around their waist line when exposed to
Figure 1. Personal genomics connect genotype to phenotype and provide insight into disease. Pharmacogenomics has helped understand some of the factors
responsible for adverse drug reactions (ADRs) caused by high exposures and factors associated with the mechanism of action of the drug and examples continue to
emerge where genetic markers identified patients at risk for serious, often life-threatening ADRs before administration of drugs. (The reader is referred to Fernald
et al. (1) and to the U.S. FDA website: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics.)
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saturated fat but not to other forms of fat. Individuals with
variants in the cyclin-dependent kinase inhibitor 2A/B
(CDKN2A/2B) pathway will be prone to having excessive
deposition of calcium in the coronary arteries. The knowledge
base of these sort of genomic risk factors allows for personal-
ized prevention in terms of dietary recommendations (very
low saturated fat diet in the case of STAT3) and supplementa-
tion (vitamin K2 at doses of 35 lcg or more has been shown
to decrease calcification of the arteries and decrease cardiac
and overall mortality and may particularly benefit individuals
with CDKN2A/2B SNPs) (2–4). For others with obesity or
cardiac risk with different genomic risk factors avoiding
snacking and early morning eating may be the best recom-
mendations, or taking aspirin or addressing inflammatory
pathways via diet or supplementation may be highly benefi-
cial. While genomics is still in its infancy and must be used in
combination with patient and family history, laboratory test-
ing, and physical exams, personalized medicine allows for
counseling to be specific to each patient. Although genomics
can help guide personalization of prevention and treatment
strategies, many challenges need to be addressed to make per-
sonalized medicine a reality (Figure 1). A patient’s genetics are
consulted only for a few diagnoses and treatment plans and
only in certain medical centers. Even if doctors had access to
their patients’ genomes today and only a small percentage of
the genome could even be used (5–8).
Nutrigenomics and clinical assessment and
genomic validation
When looking at nutrigenomics we can measure whether an
SNP is active by examining the metabolome. This includes
laboratory evaluations such as organic acid and amino acid
testing. Organic acid testing determines abnormal concentra-
tions of organic acids which serve as markers for metabolism
and show us the metabolic effects of genetic SNPs, which may
result in insufficient enzyme or co-factor availability. Amino
acids play a crucial role in the metabolome as they are the
building blocks of proteins and therefore are crucial for the
creation of enzymes and serve as substrates and products in
various metabolic pathways. One may argue that elementary
knowledge of nutrigenomics should focus on three regulatory
pathways: one-carbon (1C) metabolism, methylation, and
transsulfuration. Not only do these pathways help regulate
DNA expression, they intersect with countless other pathways
including monoamine synthesis and catabolism, the gamma
glutamyl pathway, and the urea cycle. Folate metabolism,
which supports a broader set of transformations known as 1C
metabolism, is a metabolic process that serves to activate and
transfer 1C units for biosynthetic processes including purine
and thymidine synthesis and homocysteine re-methylation.
1C transfer reactions (Figure 3) are mediated by numerous
enzymes that require nutritional coenzymes such as the B vita-
min (folate) that serves as a 1C carrier/donor and vitamins
B12, B6, and B2 and methionine. Disruptions in 1C metabol-
ism due to deficiency of the nutrients or genetic polymor-
phisms of the enzymes involved have been linked to cancer
etiology through insufficient DNA synthesis/repair and aber-
rant gene expression. Animals, unlike bacteria, yeast, and
plants, cannot synthesize folate and therefore require dietary
folate intake. In adults, insufficient dietary folate leads to
anemia. In developing fetuses, it creates a disposition to birth
defects known as neural tube defects, which involve failure of
neural tube closure early in pregnancy (9–12). The reader is
referred to the article by Lim et al. (12) that reported the
investigation of genetic susceptibility of selected 1C metabol-
ism enzymes and their interaction with diet using a compre-
hensive assessment of the metabolic pathways and its
association with the etiology of lymphomagenesis. 1C metab-
olism is essential for the creation of a methyl donor. This
pathway centers on the vitamin folate and begins with the
enzyme dihydrofolate reductase (DHFR) which requires the
niacin-derived co-factor NADPH. This enzyme is used in the
conversion of dihydrofolate into tetrahydrofolate (THF; see
Figure 2. Nutrigenomics and diet. Nutritional genomics offers insight into ways to tailor the diets of individuals and populations. Personalized nutrition, like its par-
allel in medicine, presents a new way of dealing with individual nutritive health, using a “personalized” approached sustained by high throughput technologies
including pharmacogenetics, pharmacogenomics, and epigenetics interlinked with genomic medicine (slide from the presentation of Dr Hausman-Cohen).
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Figure 3) and is both the precursor to 1C metabolism and
essential for neurotransmitter synthesis through the formation
of tetrahydrobiopterin (BH4).
Through an interlinked set of mitochondrial and cytosolic
reactions, folate metabolism supports 1C anabolic reactions.
All abbreviations are standard gene names. Certain descrip-
tions utilize the common protein name for clarity. SHMT1/
2, serine hydroxymethyl transferase, cytosolic(1)/mitochon-
drial (2); MTHFD1, methylenetetrahydrofolate dehydrogen-
ase, cyclohydrolase, and formyltetrahydrofolate synthetase 1;
MTHFD2/L, methylenetetrahydrofolate dehydrogenase 2/2-
like; MTHFD1L, monofunctional tetrahydrofolate synthase,
mitochondrial; MTFMT, mitochondrial methionyl-tRNA
formyltransferase; TYMS, thymidylate synthetase; MTHFR,
methylenetetrahydrofolate reductase; MTR, methionine syn-
thase; DHFR, dihydrofolate reductase; GART, phosphoribo-
sylglycinamide formyltransferase; ATIC, 5-aminoimidazole-
4-carboxamide ribonucleotide formyltransferase/IMP cyclo-
hydrolase; and ALDH1L1/2, cytosolic (1)/mitochondrial (2)
10-formyltetrahydrofolate dehydrogenase (11).
DHFR is greatly inhibited by the synthetic folic acid, which
has similar effects to the anticancer drug methotrexate which
inhibits DHFR to stave off growth and proliferation of cancer
cells via decreasing thymine production by rapidly dividing
cancer cells (13). When polymorphisms to DHFR are found
this SNP may be bypassed by folinic acid. The prescription
folinic acid, Leucovorin, “does not require reduction by
DHFR to participate in reactions in which folates are used as
a source of 1-carbon moieties” (14). Validation of DHFR SNP
activity is accomplished by assessing formiminoglutamate
(FIGLU), which increases when THF is insufficient. While
there are several other enzymes in 1C metabolism, none are
as well studied as methylene tetrahydrofolate reductase
(MTHFR). This enzyme has two genetic variants, C677T and
A1298C, of which the former increases homocysteine and the
latter does not. This enzyme requires as its co-factors the
riboflavin-derived FAD, NADH, and ATP. Polymorphisms to
MTHFR are associated with increased risk for neural tube
defects, miscarriage, dementia, mood disorders, peripheral
artery disease, colon cancer, and leukemia (15). This enzyme
is used to convert 5, 10-methylene THF to L-methylfolate.
This newly generated methyl donor is then donated to the
methylation cycle where, via methionine synthase (MTR) and
methionine synthase reductase (MTRR), it is used to methy-
late vitamin B12 and ultimately contributes to the formation
of the universal methyl donor S-adenosylmethyionine.
Since MTHFR requires FAD as a co-factor, the organic
acid glutaric acid which increases with riboflavin insufficiency
may be used to validate. Chronically high levels of glutaric
acid are suggested to associated with at least three inborn
errors of metabolism, including glutaric aciduria type I,
malonyl-CoA decarboxylase deficiency, and glutaric aciduria
type III. Glutaric aciduria type I (glutaric acidemia type I, glu-
taryl-CoA dehydrogenase deficiency, GA1, or GAT1) is an
inherited disorder in which the body is unable to completely
break down the amino acids lysine, hydroxylysine, and trypto-
phan due to a deficiency of mitochondrial glutaryl-CoA
dehydrogenase. Excessive levels of their intermediate break-
down products (including glutaric acid, glutaryl-CoA, 3-
hydroxyglutaric acid, and glutaconic acid) may accumulate
and can cause damage to the brain (and also other organs;
https://pubchem.ncbi.nlm.nih.gov/compound/glutaric_acid).
Figure 3. Products and compartmentalization of folate-mediated one-carbon (1C) metabolism. Through an interlinked set of mitochondrial and cytosolic reactions,
folate metabolism supports 1C anabolic reactions. All abbreviations are standard gene names. Certain descriptions utilize the common protein name for clarity.
SHMT1/2, serine hydroxymethyl transferase, cytosolic(1)/mitochondrial (2); MTHFD1, methylenetetrahydrofolate dehydrogenase, cyclohydrolase, and formyltetrahy-
drofolate synthetase 1; MTHFD2/L, methylenetetrahydrofolate dehydrogenase 2/2-like; MTHFD1L, monofunctional tetrahydrofolate synthase, mitochondrial; MTFMT,
mitochondrial methionyl-tRNA formyltransferase; TYMS, thymidylate synthetase; MTHFR, methylenetetrahydrofolate reductase; MTR, methionine synthase; DHFR,
dihydrofolate reductase; GART, phosphoribosylglycinamide formyltransferase; ATIC, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohy-
drolase; ALDH1L1/2, cytosolic (1)/mitochondrial (2) 10-formyltetrahydrofolate dehydrogenase (11).
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The methylation pathway centers around two amino acids,
methionine and homocysteine. In fact, methionine is simply
methylated homocysteine. The recycling and catabolism of homo-
cysteine may go through three routes. Half of homocysteine
catabolism involves MTR/MTRR which convert homocysteine
back to methionine using vitamin B12 as its co-factor. These
enzymes also serve to recycle methyl donors. Methylmalonic acid
(MMA), which elevates when there is a cellular vitamin B12 insuf-
ficiency, may therefore be used to validate MTR/MTRR activity.
The other half of homocysteine catabolism is accounted for by
cystathionine beta synthase (CBS), the only eliminating route.
This enzyme requires vitamin B6 as its co-factor and the organic
acid xanthurenate (when elevated) can validate SNP activity. Less
than 1% of homocysteine catabolism may also occur via betaine
homocysteine methyltransferase (BHMT) using trimethylglycine
and zinc as co-factors. One essential element of the regulation of
1C metabolism and methylation is that there must be enough
vitamin B12 present to receive the methyl donor from 1C metab-
olism. Without enough vitamin B12, folate gets trapped as L-
methylfolate and may not be recycled back to THF. Further, this
will greatly impair regulation of DNA expression. For someone
who is folate trapping, this will result in an elevation of MMA and
FIGLU. It also typically increases homocysteine and serum folate.
CBS is the bridge between methylation and transsulfuration. It
converts homocysteine to cystathione (vitamin B6–dependent).
Cystathionine may then be converted to cysteine via cysteine
gamma lyase (CTH), which is also vitamin B6–dependent.
Ultimately, this leads to the formation of glutathione, sulfate, and
taurine. SNPs to CBS may either be downregulated or upregu-
lated, causing an increase or decrease in homocysteine, respect-
ively. Upregulation may be associated with sulfur intolerance
and causes increased taurine and sulfate and decreased production
of glutathione. It is also associated with increased ammonia pro-
duction and will increase ammonia-related organic acid test
markers including orotate, citrate, and isocitrate.
Given that nutrigenetics and nutrigenomics conceptual-
izes the research into the relationship between genes and
nutrients from basic biology to clinical practice, by under-
standing how genes alter the body’s response to nutrition or
how nutrition alters the body’s response to defective genes,
scientists are unlocking the codes to health and longevity.
Profiling of genetic nutritional responses can help in the
determination of which specific foods give the best bio-
logical response, based on an individual’s DNA. The gen-
omic disposition of the individual has a direct bearing in
the control of metabolism, which is nicely illustrated here.
Nutritional genomics offers insight into ways to tailor the
diets of individuals and populations. Personalized nutrition,
like its parallel in medicine approach, presents a new way of
dealing with individual nutritive health, using a
“personalized” approached sustained by high throughput
technologies (1,16–18).
Multi-scale omics enables precision medicine: From
space flight to clinical practice
The context of omics research was extended to discuss the
role of nutritional genomics to help protect humans on a
potential space mission (19, 20). Depending upon specific
mission parameters, a mission to Mars would result in radi-
ation exposures ranging from 1,000 to 1,600 mSv (millisie-
verts) (21, 22). Nutritional genomics is being explored as one
means to protect molecular networks in astronauts entering
spaceflight radiation environments and base countermeasures
on a precision understanding of genotype and molecular
phenotype (19, 20). While conventional measures of the gen-
ome will be important (SNPs, structural variants, such as
insertion/deletion (INDEL) and copy number variation
(CNV) polymorphisms, etc.), attention to genome stability
and relevant nutritional modulators also warrants consider-
ation, potentially from the standpoint of (1) disordered 1C
metabolism (nutrients and genetic variants) that can increase
uracil substitution for thymine into the genome, representing
a mutational event (23, 24); (2) magnesium influences all
DNA repair processes, either through direct roles in DNA
repair enzymes or indirectly through Mg/ATP complexes
(25); (3) NAD (nicotinamide) status can influence DNA sta-
bility by virtue of radiation-induced PARP (poly ADP-ribosyl
polymerase) activation, where up to 200 molecules of NAD
may be consumed in the formation of a single PARP polymer
(26); and (4) elevated iron burden and associated genetic var-
iants (H63D, C282Y, S65C) can favor the formation of oxida-
tion products of DNA and RNA (27). Addressing the
convergence of individual genotype, the molecular phenotype
(nutritional metabotype), clinical phenotype, and the environ-
ment represents one means by which health, safety, and per-
formance can be optimized in humans exploring harsh
environments, such as space.
The study of cohorts such as astronauts in the NASA
Twins study necessarily involves small subject numbers.
Small subject numbers are also the rule in our precision
medicine work with military Special Forces, professional rac-
ing, NFL, NBA, U.S. Olympic teams, high altitude ascent,
Mars analog missions, commercial spaceflight, and various
clinical settings, where individualized therapeutics (counter-
measures) are the rule. Interpreting multi-scale untargeted
omics data in small N studies presents inherent challenges
of overfitting and the possible generation of false discoveries,
due to low subject (sample) numbers and high variable (ana-
lyte) numbers. These studies are also highly sensitive to the
introduction of experimental variance. For instance, batch
effects are problematic in multi-scale omics studies and,
unless accounted for, may result in modeling the specific
time (and conditions) at which analytical batches are run
(28, 29). Untargeted work with small subject numbers
should control for or annotate as many contributors to
experimental variance as is reasonably possible embracing
patients, physicians, and the laboratories conducting the
analysis. Targeted work in nutritional genomics is less sensi-
tive to generating false discoveries, with targeted assessment
being the rule in the clinical application of nutritional
genomics and precision medicine. Coupling nutritional gen-
omics with metabolite profiling can provide additional
details about the real-time intersection of genotype, diet,
environment, and lifestyle. This includes monogenic gene–
metabolite pairs (30). For instance, determination of genetic
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variants in the FADS1 (fatty acid desaturase 1) gene can be
coupled with assessment of EPA, DHA, and AA in red blood
cells to better understand the association between the gene and
its related metabolites. Polygenic scores can also be coupled
with downstream molecular measures. For instance, polygenic
scores for low-density lipoprotein (LDL) cholesterol are often
constructed based on effect sizes (31). When polygenic scores
are coupled with real-time serum measures of LDL cholesterol
(including particle number and particle phenotype), a more
in-depth understanding can be developed of the convergence
of genetics with diet and lifestyle. Polygenic scores can also be
coupled with a molecular phenotype consisting of a cluster of
associated molecular markers. By example, a polygenic score
for glucose dysregulation can minimally be coupled with the
molecular phenotype consisting of serum glucose, insulin,
hemoglobin A1c (HbA1c), and the homeostatic model assess-
ment of insulin resistance (HOMAR-IR).
Translating the research discipline of nutritional genomics
into clinical practice is among our more daunting challenges.
The field would benefit from a measured and carefully con-
sidered introduction, which would ideally be rooted in a
growing consensus within the discipline. However, the cur-
rent commercial environment faces us with a unique chal-
lenge. The availability of genetic testing to consumers ensures
that they will present clinicians with personal genetic data for
interpretation and recommendations in advance of such con-
sensus. This dynamic compels the field to accelerate the rate
at which we provide clinicians with enough rigor and training
in the clinical practice setting. Presently, there are few nutri-
tion-related professional organizations that have formally
embraced the subject or provided guidelines for its imple-
mentation (32). As the field of nutritional genomics advances,
it would benefit from the insight gained in the study and
management of inborn errors of metabolism, with the inte-
gration of data regarding genotype, molecular phenotype
(clinical chemistry), and clinical phenotype, existing on a con-
tinuum that most reliably informs clinical decisions.
Metabolic adaptability of genetic and
nutritional responses
Profiling of genetic nutritional responses can help in the
determination of which specific foods give the best bio-
logical response, based on an individual’s DNA. Of interest,
fatty acids in dietary triacylglycerols are transported from
the intestines to the rest of the body by large lipoprotein
particles called chylomicrons. Hormone signaling releases
fatty acids from adipose tissue that bind to an abundant
transport protein in serum called albumin. The fatty acids
that are synthesized in the liver are carried through the
body as triacylglycerols by very-low-density lipoprotein par-
ticles. Fat is stored in fat cells (adipocytes). Obesity, espe-
cially childhood obesity, can be due to both, that is, more
fat storage per cell and a larger number of adipocytes. In
contrast, in normal healthy adults, the onset of old age and
reduced metabolic rates leads to weight gain resulting pri-
marily from storing more fat per cell (although adults can
also add more fat cells if they become obese). The thematic
review of Saini-Chohan et al. (33) on fatty acid metabolism
is worth perusing by the reader for an illustration of the
potential genomic disposition of the individual impacting
the control of metabolism.
Full-spectrum approach to healthy metabolism
Assessment and treatment of dysmetabolic conditions
requires a “full-spectrum approach,” indicating that only
one aspect, such as genetic variants (referring to SNPs) and/
or the application of nutrigenomics, will be useful, yet per-
haps not comprehensive enough to address the multifaceted
etiology underlying the dysregulation of the glucose–insuli-
n–adipocyte nexus. Limited research indicates that nutrige-
netically tailored diets may be helpful for encouraging better
outcomes (34); however, other features, like the composition
of the gut microbiome, need deeper clinical evaluation (35).
Other areas for exploration include the impact of epigenetics
(especially methylation) and evaluating the response of a
dietary pattern in the context of one’s exposome (36). An
exposome may encompass one’s total lived experience and
relates to socioeconomic disadvantage, lifestyle factors, daily
behaviors, choices, and stress response, to name a few. It
has been suggested that not every individual has the same
exposome, by which a fair comparison of responses to a
meal can be analyzed. A meal may be metabolically proc-
essed differentially based on the culmination of one’s expo-
some. Some individuals may be at a greater disadvantage
than others due to any number of variables. Six emerging
concepts in the scientific literature that are part of this
greater spectrum of therapeutic options include: (1) the role
of tailoring one’s ancestral DNA to their dietary pattern,
such as the Japan diet, Nordic diet, Mediterranean diet, and
even the recently-proposed MedEire diet; (2) the influence
of toxin load (e.g., heavy metals such as arsenic, or even
plasticizers like bisphenol A) on obesity and diabetes, and
strategies to mitigate risk, from avoidance to tailoring
nutrients to facilitate optimized function of endogenous
enzymes responsible for metabolic detoxification; (3) the
puzzling piece of dietary diversity and whether it helps or
negatively effects body weight; (4) the pleiotropic pathways
of plants and how they can have multiple actions at the level
of cell signaling and protein kinase modulation to induce,
sensitize, or decrease dysfunctional metabolic signals; (5)
how seasonality (circadian rhythm, shift work) impacts
one’s eating pattern and propensity toward obesity and
metabolic syndrome; and (6) the relationship between food
and mood, specifically noting that obesity increases the inci-
dence of anxiety and mood disorders (37) and that, con-
versely, eating a healthy, whole, plant-based diet, such as the
Mediterranean Diet, may help with reducing depression and
encourage well-being and satisfaction (38).
Translating the science of nutrigenomics
into practice
A great deal has changed in the nutrigenetic testing environ-
ment since the first nutrigenetic tests appeared in the early
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2000s. The past two decades have seen exponential growth in
the number of genetic testing companies in the marketplace.
Direct-to-consumer companies such as 23andMe, Ancestry.
com, and Helix personify how the consumer market has
been captured with low-cost tests and high-technology, con-
sumer-friendly user interfaces. What is missing from this
conversation is the use of practitioner-based nutrigenetic
tests and the role of the health professional in their execu-
tion. Only a small percentage of genetic tests are being sold
through health practitioners, yet countless publications have
identified the health professional as key to the delivery and
translation of nutrigenetic tests. The possible reasons that
health professionals have not taken ownership of the growth,
translation, and utilization of nutrigenetic tests may reside
on the following: (1) the methodology driving nutrigenetic
test development (nutrigenetics vs nutrigenomics, associa-
tions, interactions and nutritional biochemistry, scientific
and clinical validity); (2) the professional development of
health practitioners as nutrigenomics experts (professional
associations, accreditation and certification); (3) a scarcity in
credible nutrigenomic education opportunities (inclusion in
undergraduate curricula, postgraduate diplomas and degrees,
and continuing education); (4) a network and community of
practice to support and connect practitioners across all disci-
plines; and (5) a mentorship program to support practi-
tioners through the experience of the clinical translation.
Until such time as a comprehensive nutrigenomic solution is
made available to health professionals, direct-to-consumer
companies will continue to monopolize the market. Health
professionals need to be able to evaluate the credibility of
genetic tests being offered providing explanation of the gen-
etic results based on their knowledge derived from evidence-
based learning, and application of clinical translation. These
skills are necessary to ensure that the best value is extracted
from nutrigenetic tests in an ethical and responsible manner.
Metabolic adaptability of genetic and nutritional
responses: Personalizing longevity
As the science of genomics continues to develop and unravel
the nuances in chemistry and biology that underpin the eti-
ology of diseases, clinicians and health care providers need to
not only understand but articulate this emerging science and
understand its value at the point of clinical care in order to
create effective and personalized treatment strategies. There is
a need to understand too the foundational concepts of epige-
nomics, the reversible modifications on a cell’s RNA, DNA or
histones, in order to develop a personalized approach for the
assessment and treatment of conditions with epigenetic etiolo-
gies, especially regarding cellular aging and inheritance. This
positions nutrition and gene interaction to benchmark longev-
ity and chronic disease/condition progression. Aging is a nat-
ural process that involves a decline in many physiological
functions and eventually results in death. Extensive research is
being performed in order to elucidate the biology of aging,
which emphasizes that lifestyle and genetic factors play an
important role in human longevity by protecting against age-
related chronic diseases such as cancer, cardiovascular disease,
and dementia. Evolutionary conserved nutrient-sensing path-
ways mediate the effects of dietary composition, genes, the
risk for chronic disease development, and longevity (39).
Quantity and quality of dietary intake, sedentary lifestyle, and
genetic susceptibility all contribute to an increased risk of
comorbidities for the overweight and obese. Obesity contrib-
utes to pathogenesis for a variety of diseases and conditions,
including cardiovascular diseases, type 2 diabetes, and certain
types of cancer (40), together representing the most prevalent
age-related diseases. When food intake is reduced (by dietary
restriction or fasting), organisms live longer than when fed a
normal diet (41).
A similar effect is seen when the activity of nutrient-sens-
ing pathways is reduced by mutations that reduce the inci-
dence of age-related loss of function and disease, including
tumors and neurodegeneration, and increase life-span in
model organisms of aging (42). Tumors and diabetes are also
uncommon in humans with mutations in the growth hor-
mone receptor (43), and natural genetic variants in nutrient-
sensing pathways are associated with increased human life-
span (44). Data from centenarians indicates a progressive
delay in the age at onset of physical and cognitive function
impairment, age-related diseases, and overall morbidity with
increasing age, and the relative period of time spent with dis-
ease was lower with increasing age in centenarians (45).
Genetic variations associated with improved nutrient metab-
olism may explain some of the health benefits observed in
centenarians, while people with exceptional longevity are not
distinct in terms of lifestyle factors from the general popula-
tion, suggesting that people with exceptional longevity may
interact with environmental factors differently than others
(46). Data from Blue Zones (longevity “hotspots” around the
globe), including the Seventh Day Adventists in Loma Linda,
California, further emphasize the role of nutrition in modu-
lating health span. Commonly observed combinations of diet
and other lifestyle choices (exercise, body mass index, smok-
ing status, etc.) account for increases in life expectancy of up
to 10 years (47). Despite their geographical differences, all
Blue Zones have diets in common that are (1) mostly plant-
based, including fish and high intake of nuts, (2) low in ani-
mal-based protein and saturated trans fats, and (3) high in
complex carbohydrates derived from plant-based sources
(48). These findings identify a dietary pattern, often referred
to as “Mediterranean diet,” consistently associated with the
lowest death rates and the greatest survival rates (49–51).
Prospective and randomized clinical trials demonstrate that
diets with low protein content enhance metabolic health,
promote lean physical appearance, lower blood glucose, and
decrease the risk of diabetes in humans (39, 52). A study
population from the National Institutes of Health–AARP
(American Association of Retired Persons) Diet and Health
Study cohort of half a million people aged 50 to 71 years at
baseline further supports these findings (53): Men and
women in the highest vs lowest quintile of red and processed
meat intakes (estimated based on a food frequency question-
naire administered at baseline) had elevated risks for overall
mortality, cardiovascular disease, and cancer mortality.
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The “fasting-mimicking diet” (FMD), a periodic, short-
term, low-calorie, and low-protein dietary intervention, is a
nutrition-based program focused on health and longevity
(54–58). The FMD promotes cellular protection, regener-
ation, and rejuvenation of multiple organs and systems in
old mice, thereby reducing chronic disease incidence and
extending health span. In a randomized crossover-style clin-
ical trial that included 100 generally healthy participants, the
FMD reduced body weight and trunk and total body fat,
lowered blood pressure, and decreased insulin-like growth
factor (IGF-1) in all subjects who completed the trial. A
post hoc analysis demonstrated that biomarkers associated
with cardiovascular disease risk such as body mass index,
blood pressure, fasting glucose, triglycerides, total and LDL
cholesterol, and C-reactive protein were more beneficially
affected in participants at risk for disease than in subjects
who were not at risk (58). In the main, biogerontology
research links nutrition, genes, chronic disease, and longev-
ity and thereby provides the foundation for nutrition-based
approaches to prolong healthy aging.
Neurocognition personalized: Alzheimer’s disease
and neurocognition genomics
The limitations to care for clinicians that have access to their
patients’ genomes resides on the context that only a small
percentage of the genome could be used because such data
come from association studies, which tend to identify var-
iants with small effect sizes and have limited applications for
health care. Individuals have variations in the composition of
their genetic characteristics (factored on strategies that
embrace testing for candidate-genes and genome-wide asso-
ciation) that will affect the availability of functional proteins,
which ultimately impacts functional homeostasis and the
outcome of drug therapy. The brain reflex-receptor mechan-
ism in signaling for biomarkers and availability of enzymes
for metabolism is of critical importance here. Biomarkers can
be generically defined as unique characteristics that can be
objectively measured as indicators of a biological or patho-
logical process or pharmacological response to a therapeutic
intervention, which then qualifies them to be potentially used
across the whole translational medical research process.
Biomarkers are therefore touted as the next frontier in the
realm of modern medicine as they would represent the
essentials in guiding treatment decisions that could enable
complementary matching of specific drugs with individual
patients, effective patient therapeutic dose, and management
of drug-related risks (16, 18, 59). Neurocognition is of great
interest given the fundamental role that the brain reflex
receptor mechanism plays in controlling dynamic equilib-
rium. Developments in the foundational concepts of nutrige-
nomics and pharmacogenomics would empower and
foster an effective personalized approach for the assessment
and treatment of neurocognitive conditions including
Alzheimer’s disease, autism spectrum disorders, and mood
disorders. Neural, endocrine, and metabolic mechanisms are
also critical mediators of the microbiome-CNS signaling,
which are more involved in neuropsychiatric disorders such
as autism, depression, anxiety, and stress. The integrity of
the microbiome in CNS disorders will remain a cornerstone
for developing novel prognostic and therapeutic avenues for
CNS disorders.
Alzheimer’s disease and neurocognition genomics
Dementia globally is a leading cause of death, more prevalent
than breast cancer, and has a spiraling yearly cost of over
US$800 billion to society. However, recent observational
studies have shown that mild cognitive impairment and early
dementia can be reversed using a variety of modalities
including diet, lifestyle interventions, and supplementation
that address many of the known underlying contributing
factors to Alzheimer’s disease. While globally addressing
potential risk factors based on laboratory data such as homo-
cysteine levels, vitamin B12 and vitamin D levels, free T3
levels, and hormone levels has proven beneficial, genomics
allows for not only better understanding of the pathophysi-
ology of cognitive impairment but also personalization of a
protocol for the reversal of cognitive impairment utilizing
diet, exercise, hormone replacement when appropriate, and
supplementation Apolipoprotein EE4 (ApoEE4) is the most
well recognized genomic risk factor for Alzheimer’s disease.
Looking at how ApoEE4 contributes to and interacts with
inflammation, clearance of amyloid beta, phosphorylation of
Tau, elevations of TNF-a and many other pathways can help
facilitate better understanding of the pathophysiology of
Alzheimer’s disease. At present, looking at known genomic
risk factors with published odds ratios showing combinator-
ial or independent Alzheimer’s disease risk allows for person-
alization of a prevention and intervention strategy. As a
combination of a highly disciplined nutritional approach
(generally mild ketosis using mostly plant-based sources of
fat) along with targeted supplementation and lifestyle inter-
ventions are applied, Alzheimer’s disease progression can be
prevented and often reversed with measurable improvements
in cognition and function (60, 61).
In addressing the genomics of Alzheimer’s disease, it is
important to understand how genes interact. In addition to
risk SNPs, the importance of benefit SNPs that have been
shown to decrease risk by helping to increase heat shock pro-
teins and other amyloid-clearing pathways as well as SNPs
that decrease inflammation in the brain should not be over-
looked. The role of non-inflammatory pathways such as
brain-derived neurotrophic factor (BDNF) have also been
made clear via genomics studies, and addressing these “non-
classic” genomics risk factors such as BDNF and nutrient lev-
els (zinc, choline, and magnesium) can further contribute to
positive outcomes for affected individuals. In addition to
understanding the science behind the genomics and nutrige-
nomics of Alzheimer’s disease in this disease state, under-
standing the current laws surrounding genomics privacy is of
particular import. Individuals are theoretically protected
against health care discrimination based on genomics due to
GINA (The Genetics Information Non-discrimination Act of
2008), but there are some caveats to this legislation. GINA
only prohibits insurance companies and employers with >
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15 employees from acquiring results of genetic tests. There is
no law protecting genomic information from being used for
discrimination when it comes to long-term care or life insur-
ance policies. Knowledge of genomics law is important so
that patients can be properly counseled and consented before
a genomics interpretation tool is utilized and also so discus-
sion can be made of where genomics is documented (when
does it belong in the electronic health record vs being kept as
part of an individual’s private records that are not affiliated
with any health insurance records or official documentation
that can be utilized for discrimination?). It is also immensely
important that if practitioners are going to obtain genomic
information, they feel competent to counsel patients on how
food, lifestyle, supplements, and medications can interact
with their genome so that they feel empowered not doomed
by their genomic data and understand that “their genomics
is their history, not their destiny.” In the case of Alzheimer’s
disease and cognitive impairment, working with an experi-
enced clinical nutrition specialist or dietitian is often key to
success since so many of the targeted potential intervention
strategies involve changing diet and nutrient intake.
Food, mood, and metabolism
The use of personalized nutrition to optimize diet for individ-
uals based on genetic variation, environment and needs to
incorporate the added value of personalization beyond stand-
ard "healthy" advice that includes knowledge of differential
responses to diet and variations in metabolome associations
across phenotypes. Notable examples can be deciphered from
the different patterns of key energy metabolism systems in
response to polyunsaturated fatty acid manipulation in an ani-
mal model of metabolic syndrome compared to controls. Rats
differentially bred for aerobic capacity yielded a “fit” pheno-
type and a metabolic syndrome-like phenotype (62). When
both lines were fed either a high omega-6 or a high omega-3
diet that were otherwise identical in macronutrient compos-
ition, emerging results indicate that dietary interactions
affected plasma leptin, ghrelin, adiponectin hormones, and the
orexigenic cocaine amphetamine related transcript in the
hypothalamus (62). These data demonstrated the ability of the
same diet to have opposing effects in metabolically diverse
phenotypes. In an observational analysis of 91 individuals
with bipolar disorder and 76 non-psychiatric controls, all sub-
jects maintained a 7-day diet record under the guidance and
curation of a certified nutritionist and records were extracted
into nutrient components using the Nutrition Data System for
Research (NDSR, University of Minnesota); significantly lower
intake of polyunsaturated fatty acids and variant linoleic acid
metabolism were observed in in individuals with bipolar dis-
order. There was a significant association between dietary and
plasma levels of linoleic acid and burden of disease measures
in bipolar individuals (63, 64). In a follow-up study, the
microbiome of the stools of individuals with bipolar disorder
compared to controls found community- and species-level dif-
ferences that also associated with polyunsaturated fatty acid
intake and burden of disease measures (65). These data
suggest that the gut microbiome may mediate effects of diet-
ary linoleic acid on mood disorders.
To take the context of the gut microbiome further, an
interesting and unique view of the gut ecosystem is depicted
in Figure 4 (66). This presents a multifunctional redundancy
of intrinsic property of an environment that is subject to
fluctuations. The authors argue that the gut microbiota sta-
bility may be affected within a temporal framework and, in
this context, bacteria turnover is a healthy feature expected
in the gut. In order to ensure stability in the face of constant
disturbance, microbiota species are continuously inter-
changeable by means of the metabolites produced by the
action of gene products contained in the gut bacteria.
Microbial genes and proteins and their metabolites in the gut
grow from a simple structure in early life—usually domi-
nated by bifidobacteria—to a complex structure in adults.
Microbiota species are interchangeable in terms of func-
tions by means of the metabolites produced by the action of
gene products contained in the gut bacteria. Metabolites
produced by the action of microbiota are the downstream
product of gene expression and metabolic activity and,
therefore, they can be considered as a final output within
the functional hierarchy. Metabolomics can thus provide a
reliable snapshot of the actual functional state of the gut
ecosystem. According to the model and the functional
redundancy concept, the gut ecosystem is formed by a super
species with a very large genome, composed of widely diver-
gent microbial lineages whose genomes contain functionally
similar sets of genes (represented by triangles) that would
give rise to a coordinated single metabolic outcome (repre-
sented by circles). The diversity and abundance level of
microbes, genes, proteins, and metabolites will influence
energy balance, gut motility, inflammatory tone, mucosal
integrity, appetite, and signaling, to cite but some. Also,
note that the gut key player (i.e., pathogens) may also nega-
tively influence the gut barrier, promoting inflammation (see
components in the lower part of the figure) (66).
Besides considering microbial composition and function,
it is important to consider, over time, the contribution of
resistance (no changes in microbiota composition after being
subjected to disturbance), resilience (restoration of the initial
composition after disturbance), and functional redundancy
(recovering of the initial function despite compositional
changes). These modifications are produced along a con-
tinuum and are shaped by age, geography, lifestyle-related
factors, and medication. For instance, redundancy in the
infant gut may be higher than that found in the adult gut.
Ongoing longitudinal studies are leveraging personal dense
dynamic data (PD3) clouds (67) being collected from thou-
sands of individuals. Most studies to date are designed to
assess differences between means of groups stratified by a
small number of features (treatment, phenotype, disease,
etc.), if all other human heterogeneity is accounted for by
randomization. However, this is unlikely enough for predict-
ive value for the individual since similar clinical phenotypes
may result from very different biological perturbations
across individuals. The longitudinal PD3 clouds include clin-
ical chemistries, metabolomics, proteomics, microbiomics,
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and genetics in order to follow everyone in high dimen-
sional space. The systems biology approach can enable the
understanding wellness states and identify wellness to dis-
ease transitions far before symptoms emerge so that relevant
perturbed biological networks can be identified and targeted
for reversal to wellness states. As observed by Simon Evans,
the work supports the development of scientific wellness
and its assimilation into predictive, preventative, personal-
ized, and participatory health care of the 21st century. It is
becoming very clear that autoimmune disease is a complex
entity and may represent the result of a “perfect storm” of
biological and environmental factors and that a systems-
biology approach, utilizing a wider-lens perspective, will be
required as these subjects are approached clinically.
Applying molecular DNA technology in the assessment
of the gastrointestinal microbiota as part of an
integrative approach to autoimmune disease
With the steady increase in the incidence of virtually every
autoimmune disease occurring in the Western industrialized
world, and standard treatment still relying mainly on symp-
tom control using overt immune suppression which carry
significant side effects, clinicians are rightly looking for any
advantage in the prevention and upstream management of
autoimmune disorders.
The rising incidence of autoimmune disorders including
multiple sclerosis, Crohn’s disease, type 1 diabetes, and
asthma is shown in Figure 5 (68, 69). With the concomitant
explosion of research into the microbiome, and more
Figure 4. Model representing functional redundancy in the gut ecosystem. Microbiota species are interchangeable in terms of functions by means of the
metabolites produced by the action of gene products contained in the gut bacteria. Metabolites produced by the action of microbiota are the downstream
product of gene expression and metabolic activity and, therefore, they can be considered as a final output within the functional hierarchy. Metabolomics can thus
provide a reliable snapshot of the actual functional state of the gut ecosystem. According to the model and the functional redundancy concept, the gut ecosystem
is formed by a super species with a very large genome, composed of widely divergent microbial lineages whose genomes contain functionally similar sets of genes
(represented by triangles) that would give rise to a coordinated single metabolic outcome (represented by circles). The diversity and abundance level of microbes,
genes, proteins, and metabolites will influence energy balance, gut motility, inflammatory tone, mucosal integrity, appetite, and signaling, to cite but some. Also,
note that the gut key player (i.e., pathogens) may also negatively influence the gut barrier, promoting inflammation (see components in the lower part of the
figure) (66).
Figure 5. Rising incidence of autoimmune disorders (68).
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specifically the gastrointestinal microbiota (GM), showing
linkages between specific aberrant patterns (signatures) of
dysbiosis and greater prevalence of specific chronic complex
metabolic diseases, including autoimmune conditions, there
is a natural desire to understand why these relationships
may exist, whether they are simply associations or causal,
and what mechanisms may underlie such relationships.
Examples of epidemiologic associations between gastro-
intestinal microbes and systemic autoimmune pathology
include Klebsiella: ankylosing spondylitis; Citrobacter,
Klebsiella, Proteus, and Prevotella: rheumatoid arthritis;
Bacteroidetes spp.: arthritis in general; Fusobacterium: sys-
temic sclerosis; Mycobacteria: psoriasis and Crohn’s disease;
Yersinia: Graves’ disease and Hashimoto’s disease;
Streptococcus: pediatric autoimmune neuropsychiatric disor-
ders associated with streptococcal infections (PANDAS);
Chlamydia, Salmonella, Shigella, Yesrsinia: reactive arthritis;
S Pyogenes: rheumatic fever; Camphylobacter jejuni: Guillain-
Barre syndrome; and E coli, Proteus: autoimmunity in gen-
eral (70). PANDAS occurs when the immune system produ-
ces antibodies, intended to fight an infection, and instead
mistakenly attacks healthy tissue in the child’s brain, result-
ing in inflammation of the brain (basal ganglia section) and
inducing a sudden onset of movement disorders, neuro-
psychiatric symptoms, and abnormal neurologic behaviors.
Bacterial organisms in the GM may contribute to immune
dysregulation and potentially the development of an auto-
immune disorder in an individual by mechanisms that
includes include gastrointestinal microbial-induced imbalan-
ces in Th17/Treg balance, molecular mimicry, and modula-
tion of host proteins (71–75).
The hygiene hypothesis and changes in early environmen-
tal antigen exposure was postulated and briefly explored as a
contributing factor in the emergence of the autoimmune epi-
demic in the Western industrialized societies (76). The vari-
ous available testing methodologies for evaluation of the
gastrointestinal microbiota was discussed and contrasted,
including culture-based, next-generation sequencing (molecu-
lar) and quantitative PCR (qPCR; molecular) methods. The
inherent limitations of culture-based methods (i.e., limited
ability to assess anaerobic microbes and growth of microbes
in transit after sample collection), and the strengths and
weaknesses of next-generation sequencing microbiome versus
a more targeted clinical/diagnostic-based qPCR method which
quantitates the DNA of organisms was explored from the per-
spective of the clinician (77). Of interest, the culture-based
methods are falling by the wayside, while next-generation
sequencing testing may be most appropriate for research into
the compositional signatures of the microbiota in various
cohorts of subjects and quantitative molecular methods
(qPCR) especially suited in helping clinicians to make clinical
interventional decisions with individual patients. New oppor-
tunities for proactive screening for at-risk subjects for auto-
immune disorders such as rheumatoid arthritis, ankylosing
spondylitis, inflammatory bowel diseases, diabetes, multiple
sclerosis, lupus, and others using emerging predictive anti-
body testing was reviewed and discussed from the perspective
of the clinical nutritionist and the nutritionally minded phys-
ician. The various established predictive antibodies by disease,
and their relative positive predictive value, are outlined in
Table 1. Clinical experience suggests that the use of these test-
ing methods can be more valuable if used in a truly predictive
manner in patients with family history of autoimmune disease
versus in a confirmatory fashion only after disease is sus-
pected based on overt clinical presentation (78–80).
Integrative medicine clinicians from various professional
backgrounds and fields, including clinical nutritionist and the
nutritionally minded physician, are encountering an ever-
growing population of patients/clients with autoimmune-
related disorders, especially women, who are seeking comple-
mentary care. These patients/clients are usually also receiving
primary disease management from specialists such as rheuma-
tologists. Health care providers of all types need to under-
stand both benefits and risks of standard interventions as well
as those of the evidence-based complementary and integrative
approaches available. The autoimmune disease is a complex
entity and may represent the result of a “perfect storm” of
biological and environmental factors and that a systems-biol-
ogy approach, utilizing a wider-lens perspective, will be
required as these subjects are approached clinically (80). In
the foregoing discussions, the reader can be aware that sci-
ence and technology have lead the way to growing number of
targeted therapies. Genetic disposition, environment and diet
can turn genes on and off by modifying DNA (concept of a
Table 1. Selected Predictive Antibody Tests (80).
Disease/Disorder Autoantibody Tests Positive Predictive Value Years Prior to Clinical Diagnosis
Addison’s disease Adrenal cortex antibodies 70% 10
Celiac disease Anti-tissue transglutaminaseAnti-endomysial antibodiesHLA-DQ2 or DQ8 antigens
50%–60%
50%–60%
100%
7
Hashimoto’s thyroiditis Anti-thyroid peroxidase antibodies (postpartum) 92% 7–10
Primary biliary cirrhosis Anti-mitochondrial antibodies 95% 26
Rheumatoid arthritis Rheumatoid factorAnti-cyclic citrullinated peptide
62%–88%
97%
14
Scleroderma Anti-centromere antibodiesAnti-topoisomerase I antibodies
100% 11
Sjogren’s syndrome Anti-Ro and La antibodies 73% 5
Systemic lupus erythematosus RNP, Sm, dsDNA, Ro, La, and cardioliptin antibodies 94%–100% 7–10
Type I diabetes Pancreatic islet cell Insulin65 kD glutamic acid decarboxylaseTyrosine phosphatase-like protein
43%
55%
42%
29%
14
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process widely recognized as epigenetics). Where genes are
turned on or off it is possible to modify a disease by targeting
specific genetic mutations. Seminal references (81–90), are
instructive in that they point to emerging bioinformatics
world to foster awareness and the understanding of genomic
information. For the consumer and patients there is need to
embrace care and health management through new targets
for pharmaceuticals and functional foods.
Conclusion
Genomics is a powerful tool that can help with the delivery
of personalized medicine and personalized nutrition.
Nutrigenetics/nutrigenomics conceptualize the research into
the “relationship between genes and nutrients from basic
biology to clinical practice.” By understanding how genes
alter the body’s response to nutrition or how nutrition alters
the body’s response to defective genes, scientists are unlock-
ing the codes to health and longevity. Profiling of genetic
nutritional responses can help in the determination of which
specific foods that give the best biological response, based
on an individual’s DNA. Nutritional genomics aims to
develop a rational means to optimize nutrition through the
identification of the person’s genotype, and this defines
the relationship between nutrients and human health.
Individuals cannot change their genetics, but they can eat
the right foods to support genetic predispositions and take
the right supplements to support gene variations and pro-
mote normal cell function and structure. Poor diet can be a
risk factor of disease. The understanding of the gut micro-
bial community (from composition to functional perspec-
tives), needs to be interwoven with genomic cross talk with
active gene expression, protein synthesis (enzyme availabil-
ity), and metabolism. Given that dietary components can
alter gene expression, practitioners need to now understand
that the degree to which diet influences health and disease
depends upon an individual’s genetic makeup. The advance-
ment in the use of pharmacogenomics technology must con-
tinue to be defined and embrace diagnostic, prognostic,
predictive characteristics of diseases benchmarked on
variabilities of respective biomarkers. A network-biology
approach depicting the gut microbiota is a constant
reminder to practitioners that the continuously changing in
the gut environment can help envision health as a reflection
of the diversity and composition of gut microbiota and its
metabolic status. The evidence based-outcome of discussions
throughout the 2018 American College of Nutrition confer-
ence focused on “Personalized Nutrition: Translating the
Science of NutriGenomics Into Practice.” The reader is
referred to the guidelines pertinent to pharmacotherapy,
drug development (and with a context that potential impacts
nutrition from the standpoint that the food already contain
biomolecules that have to become systemically bioavailable
in order to exert biopharmacological effect), and pharmaco-
genomics, available at the following U.S. FDA link: http://
www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory
Information/Guidances/UCM337169.pdf. The document
refers to the presence of pharmacogenomics in premarket
investigations and drug labeling and provides guidance and
recommendations on when and how genomic information
should be considered to address questions arising during
drug development and regulatory review, including study
design, data collection, and data analysis in early-phase tri-
als. While the promise of pharmacogenomics in global
health care and nutrition care needs is becoming apparent,
there is need to ensure pharmacogenomics literacy. The net
outcome would be that nutritionists, dietitians, doctors
(physicians of all categories), nurses, pharmacists, and all
health care professionals will have the knowledge base to
both counsel and advise patients. The vein is to provide
individuals with lifestyle recommendations that will help
them enjoy optimal health and the highest possible quality
of life.
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